Br[C:2]1[CH:3]=[N:4][CH:5]=[C:6]([CH:8]2[CH2:11][O:10][CH2:9]2)[CH:7]=1.[B:12]1(B2OC(C)(C)C(C)(C)O2)[O:16]C(C)(C)C(C)(C)[O:13]1.C1(P(C2CCCCC2)C2CCCCC2)CCCCC1.C([O-])(=O)C.[K+]>O1CCOCC1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.[Pd].[Pd]>[O:10]1[CH2:11][CH:8]([C:6]2[CH:7]=[C:2]([B:12]([OH:16])[OH:13])[CH:3]=[N:4][CH:5]=2)[CH2:9]1A vial containing the title compound from Example 63 Step A (45 mg, 0.21 mmol), bis(pinacolato)diboron (107 mg, 0.420 mmol), tris(dibenzylideneacetone)dipalladium (0) (38.5 mg, 0.042 mmol), tricyclohexylphosphine (23.6 mg, 0.084 mmol) and potassium acetate (61.9 mg, 0.631 mmol) in dioxane (1.0 mL) was flushed with nitrogen, sealed tightly and heated to 80° C. overnight. The reaction was then passed through a syringe filter and concentrated under reduced pressure to provide the title compound which was used without further purification.